GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Strides Pharma Science Ltd (NSE:STAR) » Definitions » Cyclically Adjusted Revenue per Share

Strides Pharma Science (NSE:STAR) Cyclically Adjusted Revenue per Share : ₹446.24 (As of Mar. 2025)


View and export this data going back to 2000. Start your Free Trial

What is Strides Pharma Science Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Strides Pharma Science's adjusted revenue per share for the three months ended in Mar. 2025 was ₹129.155. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹446.24 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Strides Pharma Science's average Cyclically Adjusted Revenue Growth Rate was 6.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Strides Pharma Science was 5.80% per year. The lowest was 5.80% per year. And the median was 5.80% per year.

As of today (2025-06-30), Strides Pharma Science's current stock price is ₹898.75. Strides Pharma Science's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ₹446.24. Strides Pharma Science's Cyclically Adjusted PS Ratio of today is 2.01.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Strides Pharma Science was 2.01. The lowest was 0.32. And the median was 0.56.


Strides Pharma Science Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Strides Pharma Science's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Strides Pharma Science Cyclically Adjusted Revenue per Share Chart

Strides Pharma Science Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 376.60 399.30 418.56 446.24

Strides Pharma Science Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 418.56 427.24 438.76 443.90 446.24

Competitive Comparison of Strides Pharma Science's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Strides Pharma Science's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Strides Pharma Science's Cyclically Adjusted PS Ratio falls into.


;
;

Strides Pharma Science Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Strides Pharma Science's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=129.155/157.5517*157.5517
=129.155

Current CPI (Mar. 2025) = 157.5517.

Strides Pharma Science Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 97.960 99.841 154.584
201509 113.501 101.753 175.741
201512 77.986 102.901 119.404
201603 103.454 102.518 158.990
201606 88.229 105.961 131.186
201609 91.445 105.961 135.968
201612 81.610 105.196 122.227
201703 64.376 105.196 96.416
201706 70.477 107.109 103.668
201709 85.904 109.021 124.144
201712 81.075 109.404 116.755
201803 73.047 109.786 104.828
201806 52.643 111.317 74.508
201809 57.975 115.142 79.329
201812 63.627 115.142 87.063
201903 60.940 118.202 81.227
201906 75.891 120.880 98.914
201909 79.869 123.175 102.160
201912 81.750 126.235 102.031
202003 58.470 124.705 73.871
202006 87.266 127.000 108.259
202009 88.527 130.118 107.192
202012 92.772 130.889 111.670
202103 94.014 131.771 112.408
202106 76.754 134.084 90.188
202109 80.421 135.847 93.270
202112 88.468 138.161 100.885
202203 90.938 138.822 103.207
202206 104.667 142.347 115.847
202209 99.831 144.661 108.727
202212 95.750 145.763 103.494
202303 100.314 146.865 107.614
202306 103.289 150.280 108.287
202309 110.639 151.492 115.065
202312 109.755 152.924 113.076
202403 113.545 153.035 116.897
202406 118.042 155.789 119.378
202409 130.377 157.882 130.104
202412 125.276 158.323 124.666
202503 129.155 157.552 129.155

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Strides Pharma Science  (NSE:STAR) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Strides Pharma Science's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=898.75/446.24
=2.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Strides Pharma Science was 2.01. The lowest was 0.32. And the median was 0.56.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Strides Pharma Science Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Strides Pharma Science's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Strides Pharma Science Business Description

Traded in Other Exchanges
Address
Strides House, Bannerghatta Road, Bilekahalli, Bengaluru, KA, IND, 560 076
Strides Pharma Science Ltd is a specialty and generic drug manufacturer. The company focuses on developing niche and complex pharmaceutical products across therapeutic segments for regulated and emerging markets. Strides' emerging-market plan focuses on branded generics for the treatment of chronic therapies. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. The company's reportable segment are; Pharmaceutical & Bio-pharmaceutical.

Strides Pharma Science Headlines

No Headlines